Press coverage about Cellectar Biosciences (NASDAQ:CLRB) has trended somewhat positive on Thursday, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellectar Biosciences earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.3922811006085 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Cellectar Biosciences (NASDAQ CLRB) opened at 1.65 on Thursday. Cellectar Biosciences has a 52-week low of $1.12 and a 52-week high of $3.19. The company’s market capitalization is $22.97 million. The stock has a 50 day moving average price of $1.60 and a 200 day moving average price of $1.84.

Cellectar Biosciences (NASDAQ:CLRB) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Equities research analysts forecast that Cellectar Biosciences will post ($0.92) earnings per share for the current year.

Several research firms have recently weighed in on CLRB. Zacks Investment Research raised Cellectar Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. ValuEngine raised Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

COPYRIGHT VIOLATION WARNING: “Cellectar Biosciences (CLRB) Earns News Sentiment Score of 0.16” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.

Insider Buying and Selling by Quarter for Cellectar Biosciences (NASDAQ:CLRB)

Receive News & Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related companies with's FREE daily email newsletter.